Celldex Therapeutics Surges 30% After Positive Phase 2 Data In Brain Cancer By: TalkMarkets November 17, 2014 at 17:41 PM EST Positive results in an interim phase 2 analysis of rindopepimut show increased survival. Read More >> Related Stocks: Celldex Therapeutics